Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam

被引：2
|
作者：
Tamma, Pranita D. [1 ]
Fan, Yunfan [2 ]
Bergman, Yehudit [3 ]
Sick-Samuels, Anna C.
Hsu, Alice J. [4 ]
Timp, Winston [2 ]
Simner, Patricia J. [3 ]
Prokesch, Bonnie C. [5 ]
Greenberg, David E. [5 ,6 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA
[5] Univ Texas Southwestern, Div Infect Dis, Dallas, TX 75390 USA
[6] Univ Texas Southwestern, Dept Microbiol, Dallas, TX 75390 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2018年 / 62卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Burkholderia cepacia complex; whole-genome sequencing; bacteremia; ceftazidime-avibactam; BETA-LACTAMASES; CYSTIC-FIBROSIS; SUSCEPTIBILITY; INFECTIONS; RESISTANCE; BLOOD;
D O I：
10.1128/AAC.02213-17
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We report our clinical experience treating a 2-month-old infant with congenital diaphragmatic hernia who experienced prolonged bacteremia with Burkholderia cepacia complex (Bcc) despite conventional antibiotic therapy and appropriate source control measures. The infection resolved after initiation of ceftazidime-avibactam. Whole-genome sequencing revealed that the isolate most closely resembled B. contaminans and identified the mechanism of resistance that likely contributed to clinical cure with this agent. Ceftazidime-avibactam should be considered salvage therapy for Bcc infections if other treatment options have been exhausted.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam
    Van Dalem, A.
    Herpol, M.
    Echahidi, F.
    Peeters, C.
    Wybo, I.
    De Wachter, E.
    Vandamme, P.
    Pierard, D.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (09)
  • [2] Susceptibility of Burkholderia cepacia Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients
    Schaumburg, Frieder
    Idelevich, Evgeny A.
    Mellmann, Alexander
    Kahl, Barbara C.
    MICROBIAL DRUG RESISTANCE, 2022, 28 (05) : 545 - 550
  • [3] Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam
    Los-Arcos, Ibai
    Len, Oscar
    Teresa Martin-Gomez, Maria
    Jose Gonzalez-Lopez, Juan
    Saez-Gimenez, Berta
    Deu, Maria
    Nuvials, Xavier
    Ferrer, Ricard
    Roman, Antonio
    Gavalda, Joan
    INFECTION, 2019, 47 (02) : 289 - 292
  • [4] Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis
    Dacco, Valeria
    Claut, Laura
    Piconi, Stefania
    Castellazzi, Luca
    Garbarino, Francesca
    Teri, Antonio
    Colombo, Carla
    TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (03)
  • [5] Atypical Burkholderia Cepacia Resistance to Ceftazidime/Avibactam and Co-trimoxazole: A Case of Open Wound Contamination and Persistent Bacteremia
    Uwumiro, Fidelis
    Edigin, Ehizogie
    Okpujie, Victory
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [6] Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
    Shields, Ryan K.
    Nguyen, M. Hong
    Chen, Liang
    Press, Ellen G.
    Potoski, Brian A.
    Marini, Rachel V.
    Doi, Yohei
    Kreiswirth, Barry N.
    Clancy, Cornelius J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)
  • [7] Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis
    Shields, Ryan K.
    Horcajada, Juan P.
    Kamat, Shweta
    Irani, Paurus M.
    Tawadrous, Margaret
    Welte, Tobias
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (07) : 1639 - 1664
  • [8] Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
    Simon, Matthew S.
    Sfeir, Maroun M.
    Calfee, David P.
    Satlin, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
  • [9] Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia
    Algwizani, Abdullah
    Alzunitan, Mohammad
    Alharbi, Ahmad
    Alsaedy, Abdulrahman
    Aljohani, Sameera
    Alalwan, Bassam
    Gramish, Jawaher
    Alothman, Adel
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2018, 11 (06) : 793 - 795
  • [10] Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series
    Spoletini, G.
    Etherington, C.
    Shaw, N.
    Clifton, I. J.
    Denton, M.
    Whitaker, P.
    Peckham, D. G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (05) : 1425 - 1429
12345